ValuEngine cut shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) from a hold rating to a sell rating in a report published on Friday.
Separately, Piper Jaffray Companies reaffirmed an overweight rating and issued a $6.00 price target on shares of Aptevo Therapeutics in a report on Thursday, October 5th.
Aptevo Therapeutics (NASDAQ APVO) traded down $0.02 on Friday, reaching $3.02. 380,200 shares of the company traded hands, compared to its average volume of 299,067. The company has a debt-to-equity ratio of 0.36, a quick ratio of 4.98 and a current ratio of 5.66. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $3.85.
Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.08. The firm had revenue of $10.76 million for the quarter. Aptevo Therapeutics had a net margin of 5.40% and a negative return on equity of 32.64%. equities research analysts anticipate that Aptevo Therapeutics will post 0.59 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Aptevo Therapeutics Inc. (APVO) Lowered to “Sell” at ValuEngine” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://ledgergazette.com/2017/11/13/aptevo-therapeutics-inc-apvo-lowered-to-sell-at-valuengine.html.
A number of hedge funds have recently added to or reduced their stakes in the business. Precept Management LLC bought a new stake in Aptevo Therapeutics during the second quarter valued at $1,210,000. Dimensional Fund Advisors LP increased its stake in Aptevo Therapeutics by 8.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock valued at $2,187,000 after purchasing an additional 78,109 shares during the last quarter. Legal & General Group Plc increased its stake in Aptevo Therapeutics by 11,751.3% during the second quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock valued at $815,000 after purchasing an additional 390,379 shares during the last quarter. Finally, Spark Investment Management LLC increased its stake in Aptevo Therapeutics by 167.4% during the second quarter. Spark Investment Management LLC now owns 61,500 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 38,500 shares during the last quarter. Hedge funds and other institutional investors own 39.19% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.